Evaluation of the effect of a combination of glucosamine and chondroitin sulfate supplemented with native (undenatured) type 2 collagen, ginger extract, B vitamins, and ascorbic acid on the clinical manifestations of different phenotypes of osteoarthritis

Objective. To evaluate the efficacy and safety of Teraflex Ultra compared with Teraflex® in patients with different phenotypes of osteoarthritis (OA).
Material and methods. A prospective comparative randomized study included 80 women aged 40–75 years with a confirmed diagnosis of knee OA (Kellgren–Lawrence stages I–III) and pain on walking ≥40 mm on a visual analogue scale (VAS). The study duration was 9 months (6 months of treatment and 3 months of follow-up). Patients were randomized into two groups. Group 1 (n=40) received Theraflex Ultra orally, 2 capsules twice daily. Group 2 (n=40) received Theraflex® orally, 1 capsule three times daily for 3 weeks, followed by 1 capsule twice daily. All patients were allowed to take nonsteroidal anti-inflammatory drugs (NSAIDs) as required: Theraleve 275 (naproxen) up to 3 tablets per day. Treatment efficacy was assessed by changes in pain intensity on the VAS, WOMAC index, KOOS scale, and EQ-5D quality-of-life questionnaire.
Results and discussion. The trial demonstrated efficacy of pharmaconutraceutical and the drug in reducing pain on walking (VAS), total WOMAC and its subscales, as well as improving KOOS and EQ-5D scores (p<0.05). However, a more pronounced and rapid clinical effect was observed in the Theraflex Ultra group. Significant differences between the groups were found in the following parameters: pain on the VAS and KOOS after 1 month of therapy (38 [26; 47] vs. 44.5 [37; 53] mm, p=0.02 and 61 [56; 72] vs. 56 [44; 68]%, p=0.04, respectively); pain on the WOMAC after 1, 3, and 9 months (149 [114; 196] vs. 197 [122.5; 254] mm, p=0.036; 104 [57; 172] vs. 158.5 [91.5; 253] mm, p=0.037; 66.5 [39; 106] vs. 111.5 [44.5; 170.5] mm, p=0.04); stiffness on the WOMAC after 1, 3, and 9 months (68 [35; 90] vs. 85 [53; 110.5] mm, p=0.04; 42.5 [18; 79] vs. 77 [25; 102] mm, p=0.03; 24.5 [15; 51] vs. 43.5 [17; 86] mm, p=0.04); functional impairment and total WOMAC after 9 months (252 [148; 440] vs. 417 [159; 705] mm, p=0.02 and 326.5 [243; 543] vs. 555.5 [240; 914.5] mm, p=0.03).
Conclusion. The results indicate that Theraflex Ultra provides a faster and more pronounced clinical effect compared with Theraflex® in patients with different phenotypes of OA.

1. Mazurov VI, Lila AM, Alekseeva LI, et al. Multimorbidity in osteoarthritis and pleiotropic effects of slow-acting symptomatic drugs. Resolution of the multidisciplinary International Expert Council. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2023;17(5):123-131. (In Russ.). doi: 10.14412/1996-7012-2023-5-123-131.

2. Lila AM, Alekseeva LI, Taskina EA, et al. Experience with olokizumab use in patients with inflammatory phenotype of osteoarthritis. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2024;18(3):14–24. (In Russ.). doi: 10.14412/1996-7012-2024-3-14-24.

3. Alekseeva LI, Taskina EA, Kashevarova NG, et al. Knee osteoarthritis and metabolic syndrome: new approaches to therapy. Nauchnoprakticheskaya revmatologiya. 2018;56(2): 157-163. (In Russ.).

4. Lila AM, Taskina EA, Alekseeva LI, et al. Symptomatic slow-acting drugs (SYSADOA): new applications. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2022; 16(2):99-106. (In Russ.). doi: 10.14412/1996-7012-2022-2-99-106.

5. Lila AM, Alekseeva LI, Taskina EA, et al. Evaluation of the effect of a combination of glucosamine and chondroitin sulfate supplemented with native (undenatured) type II collagen, ginger extract, B vitamins and ascorbic acid on clinical manifestations of OA in different disease phenotypes (preliminary results). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2024;18(6):124-127. (In Russ.). doi: 10.14412/1996-7012-2024-6-124-127.

6. Wang Z, Wang R, Yao H, et al. Clinical efficacy and safety of chondroitin combined with glucosamine in the treatment of knee osteoarthritis: a systematic review and meta-analysis. Comput Math Methods Med. 2022 Jul 25: 2022:5285244. doi: 10.1155/2022/5285244.

7. Meng Z, Liu J, Zhou N. Efficacy and safety of the combination of glucosamine and chondroitin for knee osteoarthritis: a systematic review and meta-analysis. Arch Orthop Trauma Surg. 2023 Jan;143(1):409-421. doi: 10.1007/s00402-021-04326-9.

8. Martinez-Puig D, Costa-Larrion E, RubioRodriguez N, et al. Collagen supplementation for joint health: the link between composition and scientific knowledge. Nutrients. 2023 Mar 8;15(6):1332. doi: 10.3390/nu15061332.

9. Kumar P, Bansal P, Rajnish RK, et al. Efficacy of undenatured collagen in knee osteoarthritis: review of the literature with limited meta-analysis. Am J Transl Res. 2023 Sep 15; 15(9):5545-5555.

10. Gupta A, Maffulli N. Undenatured type II collagen for knee osteoarthritis. Ann Med. 2025 Dec;57(1):2493306. doi: 10.1080/07853890.2025.2493306.

11. Sharma S, Shukla MK, Sharma KC, et al. Revisiting the therapeutic potential of gingerols against different pharmacological activities. Naunyn Schmiedebergs Arch Pharmacol. 2023 Apr;396(4):633-647. doi: 10.1007/s00210-022-02372-7.

12. Szymczak J, Grygiel-Gorniak B, Cielecka-Piontek J. Zingiber officinale Roscoe: the antiarthritic potential of a popular spice – preclinical and clinical evidence. Nutrients. 2024 Mar 5;16(5):741. doi: 10.3390/nu16050741.

13. Bartels EM, Folmer VN, Bliddal H, et al. Efficacy and safety of ginger in osteoarthritis patients: a meta-analysis of randomized placebo-controlled trials. Osteoarthritis Cartilage. 2015 Jan;23(1):13-21. doi: 10.1016/j.joca.2014.09.024.

14. Dunlap B, Patterson GT, Kumar S, et al. Vitamin C supplementation for the treatment of osteoarthritis: perspectives on the past, present, and future. Ther Adv Chronic Dis. 2021 Oct 20:12:20406223211047026. doi: 10.1177/20406223211047026.

15. Shen S, Liang Y, Zhao Y, et al. Dietary supplementation of vitamin B1 prevents the pathogenesis of osteoarthritis. Proc Natl Acad Sci U S A. 2024 Jul 23;121(30):e2408160121. doi: 10.1073/pnas.2408160121.

16. Fang Z, Hu Q, Liu W. Vitamin B6 alleviates osteoarthritis by suppressing inflammation and apoptosis. BMC Musculoskelet Disord. 2024 Jun 6;25(1):447. doi: 10.1186/s12891-024-07530-x.

17. Magaсa-Villa MC, Rocha-Gonzalez HI, Fernandez del Valle-Laisequilla C, et al. B-vitamin mixture improves the analgesic effect of diclofenac in patients with osteoarthritis: a double-blind study. Drug Res (Stuttg). 2013 Jun;63(6):289-92. doi: 10.1055/s-0033-1334963.